Literature DB >> 25079799

Hippocampal laminar distribution of tau relates to Alzheimer's disease and age of onset.

Alon Seifan1, Karen S Marder1, Jesse Mez2, James M Noble3, Etty P Cortes4, Jean Paul Vonsattel4, Lawrence S Honig1.   

Abstract

BACKGROUND: Cerebral deposition of phospho-tau in Alzheimer's disease (AD) occurs with varying patterns within hippocampus. Lamina-specific tau changes in AD may reflect trans-synaptic propagation of phospho-tau along neuroanatomical pathways.
OBJECTIVE: To study patterns of tau deposition within inner (IML) and outer (OML) molecular layers of dentate gyrus and their clinical and neuropathological correlates.
METHODS: 98 consecutive autopsied brains from the Columbia University Brain Bank were stained for phospho-tau using AT-8. Staining density was rated as High versus Low within IML and OML. Four patterns were observed among the 98 brains: High IML&OML, n = 44; High OML Only (n = 35); High IML Only (n = 5); and Low IML&OML (n = 14). Demographic, clinical, and neuropathological characteristics of these four groups were compared.
RESULTS: High IML&amp;OML subjects, versus High OML Only, were more likely to fulfill CERAD criteria for Definite AD (93% versus 66%, p < 0.01) and to have higher median Braak stage (6 versus 5, p < 0.01) and earlier mean age of onset (65.9 versus 73.7 y, p = 0.02), with similar symptom duration. Using logistic regression, the association between High IML&amp;OML and AD remained significant after adjustment for demographics but not symptom duration. In the 70 subjects with Definite AD, High IML&amp;OML was associated with younger age of onset (mean difference 3.7 years, 95%CI -6.7 to -0.7, p < 0.01), after adjustment for demographics and symptom duration.
CONCLUSIONS: Phospho-tau pathology, when prominent within both IML and OML, is associated with CERAD diagnosis of Definite AD and earlier age of onset in AD. Laminar patterns of tau deposition reflect regional involvements during disease course.

Entities:  

Keywords:  Alzheimer's disease; dentate gyrus; hippocampus; perforant pathway; tau proteins

Mesh:

Substances:

Year:  2015        PMID: 25079799      PMCID: PMC4293261          DOI: 10.3233/JAD-140279

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  32 in total

1.  Collateral projections from the median raphe nucleus to the medial septum and hippocampus.

Authors:  J T McKenna; R P Vertes
Journal:  Brain Res Bull       Date:  2001-04       Impact factor: 4.077

2.  Neurotransmitter changes in early- and late-onset Alzheimer-type dementia.

Authors:  H Arai; Y Ichimiya; K Kosaka; T Moroji; R Iizuka
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1992       Impact factor: 5.067

3.  Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum.

Authors:  Marsel Mesulam; Pamela Shaw; Deborah Mash; Sandra Weintraub
Journal:  Ann Neurol       Date:  2004-06       Impact factor: 10.422

4.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

5.  The laminar distribution of neuritic plaques in the fascia dentata of patients with Alzheimer's disease.

Authors:  B J Crain; P C Burger
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

6.  An improved approach to prepare human brains for research.

Authors:  J P Vonsattel; H Aizawa; P Ge; M DiFiglia; A C McKee; M MacDonald; J F Gusella; G B Landwehrmeyer; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1995-01       Impact factor: 3.685

7.  Alzheimer's disease is a laminar, regional, and neural system specific disease, not a global brain disease.

Authors:  B T Hyman; T Gomez-Isla
Journal:  Neurobiol Aging       Date:  1994 May-Jun       Impact factor: 4.673

Review 8.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

Review 9.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  A direct demonstration of the perforant pathway terminal zone in Alzheimer's disease using the monoclonal antibody Alz-50.

Authors:  B T Hyman; L J Kromer; G W Van Hoesen
Journal:  Brain Res       Date:  1988-05-31       Impact factor: 3.252

View more
  4 in total

Review 1.  Alzheimer's disease and chronic traumatic encephalopathy: Distinct but possibly overlapping disease entities.

Authors:  Ryan C Turner; Brandon P Lucke-Wold; Matthew J Robson; John M Lee; Julian E Bailes
Journal:  Brain Inj       Date:  2016-08-11       Impact factor: 2.311

2.  Zfra restores memory deficits in Alzheimer's disease triple-transgenic mice by blocking aggregation of TRAPPC6AΔ, SH3GLB2, tau, and amyloid β, and inflammatory NF-κB activation.

Authors:  Ming-Hui Lee; Yao-Hsiang Shih; Sing-Ru Lin; Jean-Yun Chang; Yu-Hao Lin; Chun-I Sze; Yu-Min Kuo; Nan-Shan Chang
Journal:  Alzheimers Dement (N Y)       Date:  2017-03-06

3.  Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease.

Authors:  Jacki M Rorabaugh; Termpanit Chalermpalanupap; Christian A Botz-Zapp; Vanessa M Fu; Natalie A Lembeck; Robert M Cohen; David Weinshenker
Journal:  Brain       Date:  2017-11-01       Impact factor: 15.255

4.  Hypertension Accelerates Alzheimer's Disease-Related Pathologies in Pigs and 3xTg Mice.

Authors:  Yao-Hsiang Shih; Shih-Ying Wu; Megan Yu; Sheng-Huai Huang; Chu-Wan Lee; Meei-Jyh Jiang; Pao-Yen Lin; Ting-Ting Yang; Yu-Min Kuo
Journal:  Front Aging Neurosci       Date:  2018-03-20       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.